Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Vontobel Holding Ltd. increased its stake in Regeneron Pharmaceuticals by 13.6% in the first quarter, signaling bullish ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

RedJay Asset Management purchased $1.27 million worth of Regeneron Pharmaceuticals stock in Q1, joining several other major ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

With that said, here are the 11 Best Genomics Stocks to Buy According to Hedge Funds.